Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

Фаза 2 Завершено NCT03656562

Кратко

This study is designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of treatment with either VAY736 (ianalumab) or CFZ533 (iscalimab) in patients with systemic lupus erythematosus (SLE) to enable further development of these compounds as treatment in this disease population

Percentage of Participants With SLE Responder Index (SRI)-4 Response Status at Week 29 With Reduced Steroid Dose Maintained Between Weeks 17 and 29

Baseline, Week 17 to Week 29 · Participants

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

• Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacok — Viatris Innovation GmbH
• Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With — Viatris Innovation GmbH
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2 — Hoffmann-La Roche
• Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults — Duke University
• Reducing Disparities in Medication Adherence in SLE — Duke University
• Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pa — Northwell Health

Все исследования